Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Eligibility Criteria

• * Subjects must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL, mycosis fungoides), Stage 1A, Stage 1B, or Stage 2A.
• * Subjects willing to follow the clinical protocol and voluntarily give their written informed consent
• * Female subjects not pregnant nor nursing and willing to undergo a pregnancy test within 21 days prior to treatment initiation and agree to use a medically accepted method of birth control such as oral contraceptives (birth control pill), Barrier method (condom plus spermicide or diaphragm plus spermicide) or abstaining from intercourse while on study
• * History of allergy or hypersensitivity to any of the components of SGX301
• * Pregnancy or mothers who are breast-feeding
• * Males and females not willing to use effective contraception
• * Subjects with history of sun hypersensitivity or photosensitive dermatoses (e.g., porphyria, systemic lupus erythematosus, Sjogren's, etc.).
• * Subjects whose condition is spontaneously improving.
• * Subjects receiving topical steroids or other topical treatments (e.g., nitrogen mustard) on lesions for CTCL within 2 weeks of enrollment
• * Subjects receiving systemic steroids, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment
• * Subjects who have received electron beam irradiation within 3 months of enrollment
• * Subjects with a history of significant systemic immunosuppression
• * Subjects taking other investigational drugs or drugs of abuse within 30 days of enrollment
• * Subject with any condition that, in the judgment of the PI, is likely to interfere with participation in the study
• * Subjects receiving drugs known to cause photosensitization within 2 weeks of starting SGX301 therapy unless they have not had evidence of photosensitization after receiving a stable dose of the medication for a minimum of 4 weeks.